The estimated Net Worth of Junning Lee is at least $72.9 Thousand dollars as of 18 August 2015. Junning Lee owns over 9,000 units of Theravance Biopharma Inc stock worth over $72,900 and over the last 10 years Junning sold TBPH stock worth over $0.
Junning has made over 1 trades of the Theravance Biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Junning bought 9,000 units of TBPH stock worth $116,100 on 18 August 2015.
The largest trade Junning's ever made was buying 9,000 units of Theravance Biopharma Inc stock on 18 August 2015 worth over $116,100. On average, Junning trades about 563 units every 0 days since 2014. As of 18 August 2015 Junning still owns at least 9,000 units of Theravance Biopharma Inc stock.
You can see the complete history of Junning Lee stock trades at the bottom of the page.
Junning's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: